CPRX · As filed with the SEC
Catalyst Pharmaceuticals balance sheet, by quarter
The statement as Catalyst Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED BALANCE SHEETS · USD
| USD | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 |
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets: | ||||
| Cash and cash equivalents | 755,859,000 | 709,171,000 | 689,892,000 | 652,800,000 |
| Accounts receivable, net | 130,834,000 | 126,477,000 | 106,409,000 | 65,863,000 |
| Inventory | 34,930,000 | 37,166,000 | 28,029,000 | 18,650,000 |
| Prepaid expenses and other current assets | 18,767,000 | 21,216,000 | 28,123,000 | 21,426,000 |
| Total current assets | 940,390,000 | 894,030,000 | 852,453,000 | 758,739,000 |
| Operating lease right-of-use asset, net | 1,858,000 | 1,935,000 | 2,010,000 | 2,084,000 |
| Property and equipment, net | 994,000 | 1,037,000 | 1,077,000 | 1,149,000 |
| License and acquired intangibles, net | 121,971,000 | 131,674,000 | 128,639,000 | 137,983,000 |
| Deferred tax assets, net | 55,111,000 | 52,767,000 | 48,256,000 | 50,704,000 |
| Investment in equity securities | 27,286,000 | 22,536,000 | 19,167,000 | 21,256,000 |
| Total assets | 1,147,610,000 | 1,103,979,000 | 1,051,602,000 | 971,915,000 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||
| Current Liabilities: | ||||
| Accounts payable | 7,151,000 | 11,202,000 | 9,096,000 | 5,528,000 |
| Accrued expenses and other liabilities | 125,247,000 | 135,950,000 | 119,639,000 | 107,479,000 |
| Total current liabilities | 132,398,000 | 147,152,000 | 128,735,000 | 113,007,000 |
| Operating lease liability, net of current portion | 2,235,000 | 2,350,000 | 2,461,000 | 2,572,000 |
| Other non-current liabilities | 280,000 | 209,000 | 161,000 | 309,000 |
| Total liabilities | 134,913,000 | 149,711,000 | 131,357,000 | 115,888,000 |
| Stockholders' equity: | ||||
| Preferred stock, $0.001 par value, 5,000,000 shares authorized: none issued and outstanding at March 31, 2026 and December 31, 2025 | 0 | 0 | 0 | 0 |
| Common stock, $0.001 par value, 200,000,000 shares authorized; 122,181,308 shares and 122,513,621 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 122,000 | 123,000 | 123,000 | 122,000 |
| Additional paid-in capital | 489,218,000 | 479,957,000 | 473,333,000 | 461,868,000 |
| Retained earnings | 523,349,000 | 474,188,000 | 446,789,000 | 394,006,000 |
| Accumulated other comprehensive income (loss) (Note 4) | 8,000 | 0 | 0 | 31,000 |
| Total stockholders' equity | 1,012,697,000 | 954,268,000 | 920,245,000 | 856,027,000 |
| Total liabilities and stockholders' equity | 1,147,610,000 | 1,103,979,000 | 1,051,602,000 | 971,915,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.